Mortality and length of hospital stay after bloodstream infections caused by ESBL-producing compared to non-ESBL-producing E. coli

被引:5
|
作者
Handal, Nina [1 ]
Whitworth, Jimmy [2 ]
Lyngbakken, Magnus Nakrem [3 ,4 ]
Berdal, Jan Erik [3 ,4 ]
Dalgard, Olav [3 ,4 ]
Jorgensen, Silje Bakken [1 ,5 ]
机构
[1] Akershus Univ Hosp, Dept Microbiol & Infect Control, Div Diagnost & Technol, Lorenskog, Norway
[2] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England
[3] Akershus Univ Hosp, Dept Infect Dis, Div Med, Lorenskog, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
[5] Akershus Univ Hosp, Dept Emergency Med, Div Internal Med, Lorenskog, Norway
关键词
Extended-spectrum beta-lactamases (ESBL); bloodstream infection; mortality; Enterobacterales; antimicrobial resistance; healthcare associated infection; LACTAMASE-PRODUCING ENTEROBACTERIACEAE; ESCHERICHIA-COLI; BACTEREMIA; OUTCOMES; EPIDEMIOLOGY; VALIDATION; RESISTANCE; THERAPY;
D O I
10.1080/23744235.2023.2261538
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To compare mortality and length of hospital stay between patients with ESBL-producing E. coli bloodstream infections (BSIs) and patients with non-ESBL E. coli BSIs. We also aimed at describing risk factors for ESBL-producing E. coli BSIs and time to effective antibiotic treatment for the two groups.Methods: A retrospective case-control study among adults admitted between 2014 and 2021 to a Norwegian University Hospital.Results: A total of 468 E. coli BSI episodes from 441 patients were included (234 BSIs each in the ESBL- and non-ESBL group). Among the ESBL-producing E. coli BSIs, 10.9% (25/230) deaths occurred within 30 days compared to 9.0% (21/234) in the non-ESBL group. The adjusted 30-day mortality OR was 1.6 (95% CI 0.7-3.7, p = 0.248). Effective antibiotic treatment was administered within 24 hours to 55.2% (129/234) in the ESBL-group compared to 86.8% (203/234) in the non-ESBL group. Among BSIs of urinary tract origin (n = 317), the median length of hospital stay increased by two days in the ESBL group (six versus four days, p < 0.001). No significant difference in the length of hospital stay was found for other sources of infection (n = 151), with a median of seven versus six days (p = 0.550) in the ESBL- and non-ESBL groups, respectively.Conclusion: There was no statistically significant difference in 30-day mortality in ESBL-producing E. coli compared to non-ESBL E. coli BSI, despite a delay in the administration of an effective antibiotic in the former group. ESBL-production was associated with an increased length of stay in BSIs of urinary tract origin.
引用
收藏
页码:19 / 31
页数:13
相关论文
共 50 条
  • [41] High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China
    Quan, Jingjing
    Zhao, Dongdong
    Liu, Lilin
    Chen, Yan
    Zhou, Jiancang
    Jiang, Yan
    Du, Xiaoxing
    Zhou, Zhihui
    Akova, Murat
    Yu, Yunsong
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (01) : 273 - 280
  • [42] Molecular epidemiology of ESBL-producing E. coli and K. pneumoniae: establishing virulence clusters
    Surgers, Laure
    Boersma, Peter
    Girard, Pierre-Marie
    Homor, Audrey
    Geneste, Delphine
    Arlet, Guillaume
    Decre, Dominique
    Boyd, Anders
    INFECTION AND DRUG RESISTANCE, 2019, 12 : 119 - 127
  • [43] Epidemiologic Characteristics of ESBL-Producing ST131 E. coli Identified Through the Emerging Infections Program, 2017
    Duffy, Nadezhda
    Campbell, Davina
    Reses, Hannah E.
    Basiliere, Elizabeth
    Rebolledo, Paulina A.
    Blakney, Rebekah
    Bower, Chris
    Phipps, Erin C.
    Flores, Kristina G.
    Dumyati, Ghinwa
    Tsay, Rebecca
    Kainer, Marion
    Muleta, Daniel
    Byrd-Warner, Benji
    Stanton, Richard
    Daniels, Jonathan
    Halpin, Alison
    Lutgring, Joseph
    Karlsson, Maria
    See, Isaac
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2020, 41 : S214 - S215
  • [44] High burden of infections caused by ESBL-producing MDR Escherichia coli in paediatric patients, Yangon, Myanmar
    San, Thida
    Moe, Ingyin
    Ashley, Elizabeth A.
    San, Nilar
    JAC-ANTIMICROBIAL RESISTANCE, 2021, 3 (01):
  • [45] ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital
    Tumbarello, M
    Citton, R
    Spanu, T
    Sanguinetti, M
    Romano, L
    Fadda, G
    Cauda, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) : 277 - 282
  • [46] Persistence of MRSA and ESBL-producing E . coli and K . oxytoca in river water
    Essert, Sarah M.
    Zacharias, Nicole
    Precht, Tabea
    Pankratz, Debbie
    Funken, Karolin
    Mutters, Nico T.
    Kistemann, Thomas
    Schreiber, Christiane
    HYGIENE AND ENVIRONMENTAL HEALTH ADVANCES, 2023, 7
  • [48] Prevalence of ESBL-Producing Enterobacteriaceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis
    Flokas, Myrto Eleni
    Karanika, Styliani
    Alevizakos, Michail
    Mylonakis, Eleftherios
    PLOS ONE, 2017, 12 (01):
  • [49] Global prevalence of human intestinal carriage of ESBL-producing E. coli during and after the COVID-19 pandemic
    Ng, Rita W. Y.
    Yang, Liuyue
    Lau, Sai Hung
    Hawkey, Peter
    Ip, Margaret
    JAC-ANTIMICROBIAL RESISTANCE, 2025, 7 (01):
  • [50] Clinical, phenotypic, and genotypic characteristics of ESBL-producing Salmonella enterica bloodstream infections from Qatar
    Goravey, Wael
    Tsui, Clement K. M.
    Ali, Gawahir A.
    Najim, Mostafa Suhail
    Shunnar, Khalid
    Ibrahim, Emad B.
    Ahmed, Mazen A. Sid
    Al Maslamani, Muna
    Sultan, Ali
    Skariah, Sini
    Hadi, Hamad Abdel
    IJID REGIONS, 2024, 11